Suppr超能文献

治疗感染性角膜炎的抗菌药物药物相互作用。

Antimicrobial Drug-Drug Interactions in the Treatment of Infectious Keratitis.

机构信息

Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, NY.

出版信息

Cornea. 2023 Dec 1;42(12):1555-1561. doi: 10.1097/ICO.0000000000003304. Epub 2023 Apr 27.

Abstract

PURPOSE

Infectious keratitis is a serious disease requiring immediate, intensive, and broad-spectrum empiric treatment to prevent vision loss. Given the diversity of organisms that can cause serious corneal disease, current guidelines recommend treatment with several antimicrobial agents simultaneously to provide adequate coverage while awaiting results of microbiology cultures. However, it is currently unknown how the use of multiple ophthalmic antimicrobial agents in combination may affect the efficacy of individual drugs.

METHODS

Using a panel of 9 ophthalmic antibiotics, 3 antifungal agents, and 2 antiacanthamoeba therapeutics, fractional inhibitory concentration testing in the standard checkerboard format was used to study 36 antibiotic-antibiotic combinations, 27 antibiotic-antifungal combinations, and 18 antibiotic-antiacanthamoeba combinations against both Staphylococcus aureus and Pseudomonas aeruginosa for synergistic, additive, neutral, or antagonistic drug-drug interactions.

RESULTS

We demonstrate that while most combinations resulted in no change in antimicrobial efficacy of individual components, the combination of erythromycin + polyhexamethylene biguanide was found to be antagonistic toward P. aeruginosa . Conversely, 18 combinations toward S. aureus and 15 combinations toward P. aeruginosa resulted in additive or synergistic activity, including 4 with improved activity toward both species.

CONCLUSIONS

Understanding how drug-drug interactions may affect drug efficacy is critical to selecting the appropriate combination therapy and improving clinical outcomes of this blinding disease.

摘要

目的

感染性角膜炎是一种严重的疾病,需要立即进行强化、广谱的经验性治疗,以防止视力丧失。鉴于可能导致严重角膜疾病的病原体种类繁多,目前的指南建议同时使用几种抗菌药物进行治疗,以在等待微生物培养结果的同时提供充分的覆盖范围。然而,目前尚不清楚联合使用多种眼用抗菌药物会如何影响个别药物的疗效。

方法

使用一组 9 种眼科抗生素、3 种抗真菌药物和 2 种抗棘阿米巴治疗药物,采用标准棋盘格式的部分抑菌浓度测试法,研究了 36 种抗生素-抗生素组合、27 种抗生素-抗真菌组合和 18 种抗生素-抗棘阿米巴组合对金黄色葡萄球菌和铜绿假单胞菌的协同、相加、中性或拮抗药物相互作用。

结果

我们证明,虽然大多数组合对个别成分的抗菌效果没有改变,但发现红霉素+聚六亚甲基双胍组合对铜绿假单胞菌具有拮抗作用。相反,有 18 种针对金黄色葡萄球菌和 15 种针对铜绿假单胞菌的组合具有相加或协同作用,包括 4 种对两种细菌都具有改善作用的组合。

结论

了解药物相互作用如何影响药物疗效对于选择适当的联合治疗方案和改善这种致盲性疾病的临床结局至关重要。

相似文献

1
Antimicrobial Drug-Drug Interactions in the Treatment of Infectious Keratitis.
Cornea. 2023 Dec 1;42(12):1555-1561. doi: 10.1097/ICO.0000000000003304. Epub 2023 Apr 27.
2
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD004197. doi: 10.1002/14651858.CD004197.pub5.
3
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev. 2014 Nov 10(11):CD004197. doi: 10.1002/14651858.CD004197.pub4.
4
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
5
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
Cochrane Database Syst Rev. 2022 Dec 13;12(12):CD009650. doi: 10.1002/14651858.CD009650.pub5.
6
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2017 Oct 5;10(10):CD009528. doi: 10.1002/14651858.CD009528.pub4.
8
Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5.
9
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2015 Mar 5(3):CD009528. doi: 10.1002/14651858.CD009528.pub3.
10
Delayed antibiotic prescriptions for respiratory infections.
Cochrane Database Syst Rev. 2017 Sep 7;9(9):CD004417. doi: 10.1002/14651858.CD004417.pub5.

引用本文的文献

1
Bacterial and Fungal Keratitis in a Tertiary Care Hospital from Romania.
Microorganisms. 2024 Apr 12;12(4):787. doi: 10.3390/microorganisms12040787.
2

本文引用的文献

2
Infectious keratitis: A review.
Clin Exp Ophthalmol. 2022 Jul;50(5):543-562. doi: 10.1111/ceo.14113. Epub 2022 Jun 3.
3
Global Current Practice Patterns for the Management of Exogenous Endophthalmitis: A Survey by the American Society of Ophthalmic Trauma.
Curr Eye Res. 2022 May;47(5):802-808. doi: 10.1080/02713683.2021.2016857. Epub 2022 Jan 13.
4
Expert Performance in Visual Differentiation of Bacterial and Fungal Keratitis.
Ophthalmology. 2022 Feb;129(2):227-230. doi: 10.1016/j.ophtha.2021.09.019. Epub 2021 Oct 6.
6
Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance.
Eye (Lond). 2021 Apr;35(4):1084-1101. doi: 10.1038/s41433-020-01339-3. Epub 2021 Jan 7.
9
A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00777-19. Print 2019 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验